News that daclizumab, brand name Zinbryta, has been given the go-ahead to be available through the U.K.’s National Health Service (NHS) for treating relapsing MS, at least in part of the country, is good news. But why has the decision taken so long?
Possibly, because the first decision, last September, was ‘no.’
The latest decision by the National Institute for Health and Care Excellence (NICE) covers only England and Wales. Hopefully, similar announcements will be made for people in Scotland and Northern Ireland in coming months.
The decision means the NHS will have a legal obligation to provide the treatment to people with relapsing MS, whose health care professional prescribes it to them.
But there are conditions.
Patients must have either:
- “Active” relapsing MS that’s been treated with another disease-modifying treatment,